SLC16A1 and central nervous system cancer: Interestingly, MRSI monitoring of the lactate-to-pyruvate-ratio during treatment of glioma cells with the histone deacetylase (HDAC) inhibitor vorinostat has revealed a significant decrease, accompanied by upregulation of MCT4 and MCT1 [141].